Skip to main content

Avelumab and Stereotactic Body Radiation Therapy in Treating Patients with Malignant Mesothelioma

Trial Status: Closed to Accrual

This phase I / II trial studies how well avelumab and stereotactic body radiation therapy work in treating patients with malignant mesothelioma. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving avelumab and stereotactic body radiation therapy may work better in treating patients with malignant mesothelioma.

Inclusion Criteria

  • Patient willing and able to provide written informed consent for the trial
  • Histologically or cytologically confirmed malignant pleural or peritoneal mesothelioma (MPM)
  • No plans for surgical resection
  • At least one prior line of systemic therapy; Note: Patients on prior immunotherapy are eligible
  • At least one targetable lesion appropriate for palliative SBRT and one non-target lesion
  • Karnofsky performance score (KPS) >= 70%
  • If of childbearing potential, must be willing to use highly effective mode of contraception for at least one month prior, during, and for 2 months after the end of active therapy
  • Absolute neutrophil count >= 1.5 K/mcL
  • Platelet count >= 100 K/mcL
  • Adequate renal function as defined by an estimated creatinine clearance >= 30 mL/min according to the Cockcroft-Gault formula or serum creatinine =< 1.5 x upper limit of normal (ULN)
  • Hemoglobin >= 9 g/dL (prior transfusion permitted)
  • Total bilirubin level =< 1.5 x the upper limit of normal (ULN) range
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< 2.5 x ULN or AST and ALT levels =< 5 x ULN (for subjects with documented metastatic disease to the liver)
  • If the patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy

Exclusion Criteria

  • Currently participating and receiving another study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
  • Prior radiation therapy precluding SBRT
  • Continuous oxygen use
  • Current use of immunosuppressive medication, EXCEPT for the following: a. intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); b. systemic corticosteroids at physiologic doses =< 10 mg/day of prednisone or equivalent; c. steroids as premedication for hypersensitivity reactions (e.g., computed tomography [CT] scan premedication)
  • Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent; patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible; replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment
  • Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version [v]4.03 grade >= 3)
  • Patient who rapidly progressed on prior immunotherapy, as determined by the treating physician, are not eligible
  • Prior Therapies: * Treatment with a monoclonal antibody within 4 weeks prior to study day 1 or has not recovered (i.e., >= grade 1 at baseline) from adverse events due to agents administered * Prior chemotherapy, targeted small molecule therapy, within 4 weeks prior to study day 1 or has not recovered (i.e., >= grade 1 at baseline) from adverse events due to a previously administered agent (excluding grade 2 neuropathy) * Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways) within 4 weeks prior to study day 1 or has not recovered (i.e., >= grade 1 at baseline) from adverse events
  • Comorbidities or prior conditions: * Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial * Prior organ transplantation including allogenic stem-cell transplantation * Known additional malignancy that is progressing or requires active treatment; exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy * Known history of active TB (Tuberculosis) * Known history of human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome * Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening or positive serologies indicating prior infection * Active infection requiring systemic therapy * Evidence of interstitial lung disease or active, non-infectious pneumonitis * Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (>= New York Heart Association Classification class II), or serious cardiac arrhythmia requiring medication
  • Pregnant women or women who are breastfeeding or of childbearing potential and not using a highly effective method of birth control for at least one month prior to enrollment; if the risk of contraception exists, male and female subjects must use highly effective contraception throughout the study and for at least 60 days after last avelumab treatment * Highly effective contraception includes either 2 barrier methods (diaphragm, condom by the partner, copper intrauterine device, sponge, or spermicide), or 1 barrier method and 1 hormonal method (any oral, subcutaneous, intrauterine, or intramuscular registered and marketed contraceptive agent that contains an estrogen and/or a progesterone agent)
  • Vaccination within 4 weeks prior to the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines
  • Concomitant use of the following medications * Any investigational anticancer therapy * Any concurrent chemotherapy, immunotherapy, or biologic therapy; concurrent use of hormones for non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptable * Immunosuppressive medications including, but not limited to systemic corticosteroids (> 10 mg/day prednisone or equivalent), methotrexate, azathioprine, and tumor necrosis factor alpha (TNF-alpha) blockers; use of immunosuppressive medications for the management of investigational product-related adverse event (AE)s, in subjects with contrast allergies is acceptable; in addition, use of inhaled and intranasal corticosteroids is permitted
  • Known contraindications to radiotherapy

New Jersey

Basking Ridge
Memorial Sloan Kettering Basking Ridge
Contact: Andreas Rimner
Phone: 212-639-6025
Memorial Sloan Kettering Monmouth
Contact: Andreas Rimner
Phone: 212-639-6025
Memorial Sloan Kettering Bergen
Contact: Andreas Rimner
Phone: 212-639-6025

New York

Memorial Sloan Kettering Commack
Contact: Andreas Rimner
Phone: 212-639-6025
New York
Memorial Sloan Kettering Cancer Center
Contact: Andreas Rimner
Phone: 212-639-6025
Memorial Sloan Kettering Nassau
Contact: Andreas Rimner
Phone: 212-639-6025
West Harrison
Memorial Sloan Kettering Westchester
Contact: Andreas Rimner
Phone: 212-639-6025


I. To evaluate the safety of avelumab plus stereotactic body radiation therapy (SBRT).


I. To assess overall response rate (ORR) using modified Response Evaluation Criteria in Solid Tumors (RECIST) for mesothelioma treated with SBRT and avelumab.

II. To assess response of irradiated (in-field) and unirradiated (out-of-field) lesions defined by RECIST 1.1 for extrathoracic disease.

III. To assess progression-free and overall survival.


I. To evaluate T-cell infiltration and phenotype both in- and outside the irradiated field, serum immune phenotype before and after avelumab plus SBRT.

II. Correlate imaging response (diffusion weighted [DW]/dynamic contrast-enhanced magnetic resonance imaging [DCE-MRI] and positron emission tomography [PET]) with biopsy sample results.


Patients receive avelumab intravenously (IV) on day 1. Cycles repeat every 2 weeks for up to 24 months in the absence of disease progression or unaccepted toxicity. After 2 cycles of avelumab, patients undergo SBRT.

After completion of study treatment, patients are followed up at 30 and 90 days and then every 2 months thereafter.

Trial Phase Phase I/II

Trial Type Treatment

Lead Organization
Memorial Sloan Kettering Cancer Center

Principal Investigator
Andreas Rimner

  • Primary ID 17-358
  • Secondary IDs NCI-2018-00145
  • ID NCT03399552